Hans Barella has, for the past 30 years, occupied several key positions at Philips Medical Systems, including commercial, marketing and technical roles. He became member of the top management team in 1985 and was appointed President and CEO of Philips Medical Systems in 1997. During this time, he initiated an ambitious acquisition program and assembled five major companies into one organization dedicated to diagnostics, treatment and patient monitoring.

Additionally, from 1992 to 1996, was Chairman of COCIR: European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry.

Hans Barella has been a member of the Board of Directors of Elekta AB, Sweden since 2003.

Mr. Barella has an Masters of Business Administration (MBA) and an Electronic Engineering degree.

Between 1993 and 1996, Philippe Boucheron worked at BioCapital LP, one of the largest Canadian venture capital funds focusing on biotechnology.

Between 1997 and 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris spending a significant part of his time following French and European biotech companies.

In 2000, he co-founded Bioam and became investment Manager, then Managing Partner in 2004. He is on the board of Aureus Pharma, Libragen, Ademtech, Integragen, Cryolog, SSI and TxCell.

Aris works primarily with companies developing innovative medical equipement, diagnostics and new technology for the healthcare sector.

He has been an active venture capitalist and private equity investor in Europe for more than 9 years. He has also taken an active role in managing investment funds with Deutsche Bank’s and Credit Suisse First Boston.

He has a degree in Mechanical Engineering from Imperial College , London. An MS in Mechanical Engineering from Massachussettes Institute of Technology and an MBA from INSEAD.

In 1986, Dr.Francke  received a Masters of Science in Physics and Mathematics from the Royal Institute of Technology (KTH) in Sweden,

Between 1987 and 1991, Dr. Francke worked on his PhD in particle physics at CERN. He was named Associate professor in 1996.

Between 1991 and 2000, Dr. Francke was a senior scientist in astroparticle physics he was key in developing radiation instruments for space research mainly for  NASA.

Dr. Franke has also collaborated with  CERN in Switzerland, the CNRS in France, KHT in Sweden, as well as, the University of New Mexico in the United States.

He studied French at Geneva University, and  completed his MBA at the Stockholm School of Economics.

Dr. Francke is on the board of directors of XCounter AB and of Supersonicimagine.

Between 2000 and 2002 Dr. Francke was on the Board of Directors for  LightLab AB, a Swedish company working with mercury free low energy lighting.

Tom Francke holds more than 40 patents and is the author of hundreds of  scientific publications. He was also editor  of the scientific newspaper “Nuclear Instruments and Methods in Physics Research” which specializes in radiation implementations.

Jean-Michele began his career in Research & Development for Sumitomo Rubber Industries.  After a move to Canada he joined  Innovatech du Grand Montreal and later CDP Capital where he was actively involved in capital investment projects for companies in Europe, USA and Canada. 

Jean-Michele Petit is a graduate in chemistry from the Ecole National Supérieure de Chimie de Paris . He also holds an MBA in Buisness Administration from McGill University , Montreal.

Alexia started her career in 1996 as project leader for Chiron Vaccines. She then worked for Parteurop Développement as project manager for innovative projects and start-ups in the biotechnology sector.

She became an associate for Sofinnova Partners in 1999 and was actively involved in the decision-making and follow-up of investments in companies  involved with biotechnology and medical devices.

Alexia joined Crédit Agricole Private Equity in January 2005 as a partner in the Life Sciences sector.

She is also an investor in Biolipox (inflammatory diseases), Fovea Pharmaceuticals (ophthalmology) and in Mutabilis (infectious diseases).

Prior to working in the venture capital industry Erich Schlick spent 15 years with BASF Pharma Knoll AG, including 10 years as an executive board member with worldwide responsibility for preclinical and clinical R&D. He also obtained worldwide patents for five products in  cardiovascular, metabolic and pain releif. In 1993, he established a partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira.